Foundations for Boron Neutron Capture Therapy of High-Grade Astrocytomas

  • L. G. Salford
  • C. P. Ceberg
  • A. Brun
  • A. Persson
  • R. B. R. Persson


The incidence of tumors in the central nervous system is 10–15 per 100.000 per year. Brain tumors are the second leading cause of cancer-related deaths in children under 15 years of age, and the third for the group between 15 and 34 years of age. The gliomas, i.e. tumors emanating from the glia, compose the majority of all malignancies of the brain; the astrocytomas constitute about 45% of all brain tumors, the oligodendrogliomas about 5%. Astrocytoma grades III–IV1 (equivalent to malignant gliomas or glioblastoma multiforme) are highly malignant, while astrocytoma grades I–II are less malignant. A large portion of the low-grade astrocytomas evolve into grades III–IV as a result of progressive dedifferentiation. Patients with high-grade astrocytomas are still beyond cure in spite of extensive surgery, improved radiotherapy and combination chemotherapy. Median survival time after the first operation for an astrocytoma grade III–IV is at best about 14 months, and only exceptional cases (3‰) survive more than 10 years.


Neutron Capture Boron Concentration Boron Neutron Capture Therapy Relative Biological Effectiveness Boron Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J.W. Kernohan, R.F. Mabon, H.J. Svien and A.V. Adson, A simplified classification of the gliomas, Proc Staff Meet Mayo Clin 24: 71, 1949.PubMedGoogle Scholar
  2. 2.
    C.P. Ceberg, L.G. Salford, A. Brun, R.J.B. Hemler and B.R.R. Persson, Neutron Capture Imaging of B-10 in tissue specimens, Radiother Oncol 26: 139, 1993.PubMedCrossRefGoogle Scholar
  3. 3.
    C.P. Ceberg, L.G. Salford and B.R.R. Persson, Quantitative boron measurements in tissue specimens, in: “CLINCT BNCT Workshop”, HUT report series TKK-F-A718, Helsinki, 1994, pp. 136–139.Google Scholar
  4. 4.
    C.P. Ceberg, “Pharmacokinetics and biodistribution of boron compounds”. Ph.D. thesis, Lund University, Lund, 1994.Google Scholar
  5. 5.
    V.P. Bond, M.N. Varma, C.A. Sondhaus and L.E. Feinendegen, An alternative to absorbed dose, quality, and RBE at low exposures, Radiat Res 104: S52, 1985.CrossRefGoogle Scholar
  6. 6.
    D. Gabel, R.G. Fairchild, B. Larsson B and H.G. Börner, The relative biological effectiveness in V79 chinese hamster cells of the neutron capture reactions in boron and nitrogen, Radiat Res 98: 307, 1984.PubMedCrossRefGoogle Scholar
  7. 7.
    A.T. Aas, “Experimental brain tumor metabolism and therapy”, Ph.D. thesis, Lund University, Lund, 1994.Google Scholar
  8. 8.
    H. Hatanaka and Y. Nakagawa, Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy, Int J Radiat Oncol Biol Phys 28: 1061, 1994.PubMedCrossRefGoogle Scholar
  9. 9.
    N.R. Clendenon, R.F. Barth, W.A. Gordon, J.H. Goodman, F. Alam and A.L. Staubus, Boron neutron capture therapy of a rat glioma, Neurosurgery 26: 47, 1990.PubMedCrossRefGoogle Scholar
  10. 10.
    J.W. Hopewell, G.M. Morris and J.A. Coderre, Determination of biological parameters for the safe application of BNCT, in: “CLINCT BNCT Workshop”, I{UT report series TKK-F-A718, Helsinki, 1994, pp. 86–93.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • L. G. Salford
    • 1
  • C. P. Ceberg
    • 2
  • A. Brun
    • 4
  • A. Persson
    • 3
  • R. B. R. Persson
    • 2
  1. 1.Department of NeurosurgeryLund UniversityLundSweden
  2. 2.Department of Radiation PhysicsLund UniversityLundSweden
  3. 3.Department of BiochemistryLund UniversityLundSweden
  4. 4.Department of NeuropathologyLund UniversityLundSweden

Personalised recommendations